The 12 weeks data showed positive results demonstrating an increase in ‘on’ time and decrease in ‘off’ time without troublesome dyskinesias.
Abbott said the primary efficacy endpoint is change from baseline to endpoint in ‘off’ time at 54 weeks.
At 12 weeks, patients reported an average of 3.9 fewer hours of ‘off’ time and 4.6 additional hours of ‘on’ time without troublesome dyskinesias.
University of Cincinnati Neuroscience Institute Neurology assistant professor and lead investigator of the study Alberto Espay said with advanced Parkinson’s disease, the goal of treatment is to provide patients with as much ‘on’ time as possible, while limiting the troublesome dyskinesias they may experience.
"The interim data from this study of LCIG show clinically meaningful improvements in these important measures," Espay said.